Goldman Sachs Takes Control Of Synthon

Current Owners BC Partners Sell Majority Share But Retain ‘Significant Stake’

 
• By Dave Wallace

Synthon’s current owners, BC Partners, are selling a controlling stake in the Dutch complex generics specialist to Goldman Sachs Asset Management.

Goldman Sachs has laid out its rationale for the Synthon deal (Shutterstock)

More from Deals

More from Strategy